About: http://data.cimple.eu/news-article/89a4ac831d92a0a2536385b43a735e96f4611dd8935102508680e75b

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/89a4ac831d92a0a2536385b43a735e96f4611dd8935102508680e75b Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Pharmaceuticals giant Johnson & Johnson on Thursday submitted an application for emergency authorization of its Covid-19 vaccine with US health authorities, the company said in a statement. The process could take several weeks, but at the end of it the vaccine would be the third authorized in the United States, after those of Pfizer-BioNTech and Moderna. J&J subsidiary Janssen Biotech "has submitted an application to the US Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate," the statement read. The new vaccine is highly anticipated because it has two big logistical advantages: it can be stored at refrigerator temperatures rather than in special freezers, significantly easing distribution; and it requires just one dose. Following J&J's request, the FDA is expected to convene its advisory committee on vaccines, which will deliver its opinion after studying the data from clinical trials. It will be responsible for determining whether the benefits of the vaccine outweigh the risks. That step took about three weeks for the Pfizer-BioNTech and Moderna vaccines, but could be faster this time around. The final green light will then be given, probably the next day. J&J announced at the end of last week the first results of its clinical trials, carried out on nearly 44,000 people in eight countries. The vaccine was overall 66 percent effective, the company said. And it is 85 percent effective in preventing severe forms of the disease. But these results also raised a concern: the shot was more effective in the United States (72 percent), than in South Africa (57 percent), where a variant that had appeared in the country has now became dominant. wat/ft
schema:headline	J&J requests emergency authorization for Covid vaccine
schema:mentions	Emergency Use Authorization Wat Refrigerator Johnson & Johnson Food and Drug Administration South Africa Coronavirus disease Vaccine United States Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Janssen Biotech Memphis Bleek
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-02-04 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	81 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software